Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Weibo Zhang, Siyuan He, Liam Wilson, Astrid Foix-Colonier, Maud Pacou, Youwei Zhu, Yi Zhu, Lili Xue, Yanfeng Wang, Junmei Li, Yanli Liu & Jun Cai. (2023) Factors Influencing Patient and Caregiver Preferences for Antipsychotic Treatment of Schizophrenia in China: A Discrete Choice Experiment. Patient Preference and Adherence 17, pages 1421-1430.
Read now
Read now
Ibrahim Turkoz, Mehmet Daskiran, H Lynn Starr, Dean Najarian, Oliver Lopena, Camilo Obando, Alexander Keenan, Carmela Benson & Srihari Gopal. (2022) Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections. Neuropsychiatric Disease and Treatment 18, pages 1927-1937.
Read now
Read now
Marit B. Rise, Liv Os Stølan, Anette Erdner, Berith Hedberg, Katja Stahl, Jesper Riise, Erik Jedenius & Jette Møllerhøj. (2021) Patients’ perspectives on three-monthly administration of antipsychotic treatment with paliperidone palmitate – a qualitative interview study. Nordic Journal of Psychiatry 75:4, pages 257-265.
Read now
Read now
Vivien Yeo, Michelle Dowsey, Victoria Alguera-Lara, Jemimah Ride, Emily Lancsar & David J. Castle. (2021) Antipsychotic choice: understanding shared decision-making among doctors and patients. Journal of Mental Health 30:1, pages 66-73.
Read now
Read now
Maju Mathews, Srihari Gopal, Isaac Nuamah, Ludger Hargarter, Adam J Savitz, Edward Kim, Wilson Tan, Bernardo Soares & Christoph U Correll. (2019) Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia. Neuropsychiatric Disease and Treatment 15, pages 1365-1379.
Read now
Read now
Alicia Lopez & Jose Rey. (2019) Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice. Neuropsychiatric Disease and Treatment 15, pages 449-456.
Read now
Read now
John FP Bridges, Kathleen Beusterien, Stephan Heres, Pedro Such, Joaquín Sánchez-Covisa, Anna-Greta Nylander, Elcie Chan & Anne de Jong-Laird. (2018) Quantifying the treatment goals of people recently diagnosed with schizophrenia using best–worst scaling. Patient Preference and Adherence 12, pages 63-70.
Read now
Read now
Miquel Bioque & Miquel Bernardo. (2018) The current data on the 3-month paliperidone palmitate formulation for the treatment of schizophrenia. Expert Opinion on Pharmacotherapy 19:14, pages 1623-1629.
Read now
Read now
Claudio Brasso, Silvio Bellino, Paola Bozzatello, Cristiana Montemagni & Paola Rocca. (2017) Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia. Neuropsychiatric Disease and Treatment 13, pages 2767-2779.
Read now
Read now
Articles from other publishers (12)
Aaron T. Brah, Douglas Barthold, Brett Hauber, Ann C. Collier, Rodney J. Y. Ho, Vincent C. Marconi, Jane M. Simoni & Susan M. Graham. (2022) The systematic development of attributes and levels for a discrete choice experiment of HIV patient preferences for long-acting antiretroviral therapies in the United States. AIDS Research and Therapy 19:1.
Crossref
Crossref
Yumi Aoki, Yukari Yaju, Tomohiro Utsumi, Leigh Sanyaolu, Marianne Storm, Yoshikazu Takaesu, Koichiro Watanabe, Norio Watanabe, Edward Duncan & Adrian GK Edwards. (2022) Shared decision-making interventions for people with mental health conditions. Cochrane Database of Systematic Reviews 2022:11.
Crossref
Crossref
Nichole GoodsmithAmy N. CohenAnthony W. P. FlynnAlison B. HamiltonGerhard HellemannNancy Nowlin-FinchAlexander S. Young. (2021) Computerized Conjoint Analysis of the Weight Treatment Preferences of Individuals With Schizophrenia. Psychiatric Services 72:3, pages 288-294.
Crossref
Crossref
Jette Møllerhøj, Liv Os Stølan, Anette Erdner, Berith Hedberg, Katja Stahl, Jesper Riise, Erik Jedenius & Marit B. Rise. (2020) “I live, I don't work, but I live a very normal life”—A qualitative interview study of Scandinavian user experiences of schizophrenia, antipsychotic medication, and personal recovery processes. Perspectives in Psychiatric Care 56:2, pages 371-378.
Crossref
Crossref
Bennett Levitan, Rachael L. DiSantostefano & Scott Evans. 2019. Pharmacoepidemiology. Pharmacoepidemiology
867
896
.
Christopher Weyant, Margaret L. Brandeau & Sanjay Basu. (2019) Personalizing Medical Treatment Decisions: Integrating Meta-analytic Treatment Comparisons with Patient-Specific Risks and Preferences. Medical Decision Making 39:8, pages 998-1009.
Crossref
Crossref
Juhaeri Juhaeri. (2019) Benefit–risk evaluation: the past, present and future. Therapeutic Advances in Drug Safety 10, pages 204209861987118.
Crossref
Crossref
Eline van Overbeeke, Chiara Whichello, Rosanne Janssens, Jorien Veldwijk, Irina Cleemput, Steven Simoens, Juhaeri Juhaeri, Bennett Levitan, Jürgen Kübler, Esther de Bekker-Grob & Isabelle Huys. (2019) Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review. Drug Discovery Today 24:1, pages 57-68.
Crossref
Crossref
Nagesh Pai & Matthew Warden. (2018) Early Australian experience in the maintenance of schizophrenia management with 3-monthly paliperidone palmitate. Australasian Psychiatry 26:6, pages 628-634.
Crossref
Crossref
Juan Marcos Gonzalez, F. Reed Johnson, Bennett Levitan, Rebecca Noel & Holly Peay. (2018) Symposium Title: Preference Evidence for Regulatory Decisions. The Patient - Patient-Centered Outcomes Research 11:5, pages 467-473.
Crossref
Crossref
Alan B. Ettinger, John A. Carter & Krithika Rajagopalan. (2018) Patient versus neurologist preferences: A discrete choice experiment for antiepileptic drug therapies. Epilepsy & Behavior 80, pages 247-253.
Crossref
Crossref
Victoria Alguera-Lara, Michelle M Dowsey, Jemimah Ride, Skye Kinder & David Castle. (2017) Shared decision making in mental health: the importance for current clinical practice. Australasian Psychiatry 25:6, pages 578-582.
Crossref
Crossref